Compare DexCom, Inc. (DXCM) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs SkyWest Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while SkyWest Inc trades at $96.52 (market cap $3.75B). The key difference: DexCom, Inc. is far larger — about 8.5× SkyWest Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and SkyWest Inc for 8 Days on average.
| DXCM | SKYW | |
|---|---|---|
Market Cap | $31.86B | $3.75B |
Volume | 3,607,070 | 196,324 |
Sector | Health | Industrials |
52-Week High | $92.34 | $115.94 |
52-Week Low | $54.84 | $78.40 |
Typical Hold Time | 62 Days | 8 Days |
Enterprise Value | $31.32B | $5.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
SkyWest (SKYW) trades at $96.73, up 0.09% on the day, with a bearish technical signal but strong fundamentals including a P/E of 9.6 and net income margin of 9.78%. Recent earnings show mixed results, with a Q1 2026 beat but a Q2 2026 miss. The company is expanding its fleet and flying agreements, supporting growth amid cost pressures.
The outlook is cautiously optimistic, with a consensus price target of $112 offering 16% upside. Risks include execution on cost control and competitive pressures, but low valuation and analyst buy ratings suggest potential for recovery if operational trends improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
